BOLD
Price
$1.43
Change
+$0.03 (+2.14%)
Updated
Jun 18 closing price
Capitalization
32.12M
59 days until earnings call
Intraday BUY SELL Signals
DNA
Price
$9.17
Change
+$0.62 (+7.25%)
Updated
Jun 18 closing price
Capitalization
599.03M
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BOLD vs DNA

BOLD vs DNA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BOLD vs. DNA commentary
Jun 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BOLD is a Hold and DNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 19, 2026
Stock price -- (BOLD: $1.40 vs. DNA: $8.55)
Brand notoriety: BOLD and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BOLD: 25% vs. DNA: 92%
Market capitalization -- BOLD: $32.12M vs. DNA: $599.03M
BOLD [@Biotechnology] is valued at $32.12M. DNA’s [@Biotechnology] market capitalization is $599.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.63B to $0. The average market capitalization across the [@Biotechnology] industry is $1.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BOLD’s FA Score shows that 1 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • BOLD’s FA Score: 1 green, 4 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both BOLD and DNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BOLD’s TA Score shows that 3 TA indicator(s) are bullish while DNA’s TA Score has 6 bullish TA indicator(s).

  • BOLD’s TA Score: 3 bullish, 5 bearish.
  • DNA’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, DNA is a better buy in the short-term than BOLD.

Price Growth

BOLD (@Biotechnology) experienced а +1.45% price change this week, while DNA (@Biotechnology) price change was +7.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.61%. For the same industry, the average monthly price growth was +8.78%, and the average quarterly price growth was +2225.89%.

Reported Earning Dates

BOLD is expected to report earnings on Aug 17, 2026.

DNA is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+2.61% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($599M) has a higher market cap than BOLD($32.1M). BOLD YTD gains are higher at: 16.667 vs. DNA (2.888). BOLD has higher annual earnings (EBITDA): -59.47M vs. DNA (-251.5M). DNA has more cash in the bank: 373M vs. BOLD (92.8M). BOLD has less debt than DNA: BOLD (48.3M) vs DNA (411M). DNA has higher revenues than BOLD: DNA (151M) vs BOLD (0).
BOLDDNABOLD / DNA
Capitalization32.1M599M5%
EBITDA-59.47M-251.5M24%
Gain YTD16.6672.888577%
P/E Ratio0.16N/A-
Revenue0151M-
Total Cash92.8M373M25%
Total Debt48.3M411M12%
TECHNICAL ANALYSIS
Technical Analysis
BOLDDNA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
88%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
BOLD
Daily Signal:
Gain/Loss:
DNA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BOSC4.320.05
+1.17%
B.O.S. Better Online Solutions
OVLY33.64-0.09
-0.27%
Oak Valley Bancorp (CA)
TJX164.13-2.19
-1.32%
TJX Companies
FNB18.10-0.28
-1.52%
FNB Corp
WWW16.70-1.04
-5.86%
Wolverine World Wide

BOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, BOLD has been loosely correlated with TVTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BOLD jumps, then TVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLD
1D Price
Change %
BOLD100%
-0.71%
TVTX - BOLD
37%
Loosely correlated
+1.42%
ACET - BOLD
36%
Loosely correlated
+4.38%
DNA - BOLD
32%
Poorly correlated
+4.14%
RXRX - BOLD
31%
Poorly correlated
-2.20%
CRBU - BOLD
31%
Poorly correlated
-2.96%
More

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with VCYT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
+4.14%
VCYT - DNA
58%
Loosely correlated
+0.73%
RXRX - DNA
51%
Loosely correlated
-2.20%
ABCL - DNA
47%
Loosely correlated
+6.88%
ABSI - DNA
44%
Loosely correlated
+2.57%
AXON - DNA
44%
Loosely correlated
-2.84%
More